Public-interest Multicenter Umbrella Trial Based on Genetic Analysis in Korean Head and Neck Cancer and Esophageal Cancer Patient - Part 1 (HNSCC)]
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Abemaciclib (Primary) ; Alpelisib (Primary) ; Durvalumab (Primary) ; Nintedanib (Primary) ; Poziotinib (Primary) ; Tremelimumab (Primary)
- Indications Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Results (n=93) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results (n=96) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.